Ted Love, now the chair of biotech's big trade group, talks drug access, leadership and 'crazy' co-pays
Love was CEO of sickle cell disease drug maker Global Blood Therapeutics in San Francisco before its acquisition last year by Pfizer. He begins his two-year stint as chair of BIO's board at a critical time for the life sciences industry. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 7, 2023 Category: Biotechnology Authors: Ron Leuty Source Type: news
Ted Love, now the chair of biotech's big trade group, talks drug access, leadership and 'crazy' co-pays
Love was CEO of sickle cell disease drug maker Global Blood Therapeutics in South San Francisco before its acquisition last year by Pfizer. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 7, 2023 Category: Health Management Authors: Ron Leuty Source Type: news
Sickle Cell Disease Poses Major Risk for Pregnant Black Patients
(MedPage Today) -- Sickle cell disease (SCD) was associated with four-fold increased risk of severe maternal morbidity (SMM), according to a large cohort study.
The condition accounted for 8.9% of disparities in SMM between Black and white patients... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 5, 2023 Category: American Health Source Type: news
Gene Therapy Not Cost-Effective for Sickle Cell by Conventional Measures
MONDAY, June 5, 2023 -- For persons with sickle cell disease (SCD), gene therapy seems not to be cost-effective per conventional cost-effectiveness analysis (CEA) standards and can be equitable per distributional CEA (DCEA) standards, which... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 5, 2023 Category: Pharmaceuticals Source Type: news
Can Gene Therapy for Sickle Cell Disease Be Cost-Effective?
(MedPage Today) -- Gene therapy may not be cost-effective in treating patients with sickle cell disease (SCD) via conventional cost-effectiveness analysis standards, but it can be an equitable strategy when using a distributional cost-effectiveness... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 2, 2023 Category: American Health Source Type: news
Barclays ups bluebird rating to overweight, citing sickle cell opportunity
(Source: Reuters: Health)
Source: Reuters: Health - June 1, 2023 Category: Consumer Health News Source Type: news
Sickle Cell Gene Therapy Can Cure, But Costs Almost $3 Million. Who Will Pay?
WEDNESDAY, May 31, 2023 -- An exceptionally pricey gene therapy cure for sickle cell disease could soon be available, but it’s not clear whether insurance companies will balk at the cost and deny coverage.
On the surface, the gene therapy... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 31, 2023 Category: General Medicine Source Type: news
Unemployment, Depression Tied to Pain Frequency in Sickle Cell Disease
(MedPage Today) -- Employment status, depression, sex, and age were all associated with pain frequency among patients with sickle cell disease (SCD), according to researchers.
In a cross-sectional study of more than 2,000 SCD patients, they found... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 22, 2023 Category: Hematology Source Type: news
Study Explores Correlates of Pain Associated With Sickle Cell
FRIDAY, May 19, 2023 -- Correlates of pain associated with sickle cell disease (SCD) include depression, age, sex, and employment status, according to a study published online May 18 in JAMA Network Open.
Kelly M. Harris, Ph.D., from the Washington... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 19, 2023 Category: Pharmaceuticals Source Type: news
ICER ’s Positive Cost-Effectiveness Assessment Lends Support For New Sickle Cell Disease Gene Therapies
The important takeaway is that these gene therapies can be cost-effective and don ’t necessarily break the bank. Too often the conversation around a therapy's price is fixated on eye-popping numbers and not value. It's laudable that ICER has redirected us to a discussion of value. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 2, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
His sickle cell disease brought agony. Gene therapy is bringing hope.
The first gene therapies for this debilitating disease will be reviewed by regulators this year, potentially sparking a health-care revolution. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - April 28, 2023 Category: Consumer Health News Authors: Carolyn Y. Johnson Source Type: news
A new era for treating sickle cell disease could spark a health-care revolution
The first gene therapies for this debilitating disease will be reviewed by regulators this year. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - April 28, 2023 Category: Consumer Health News Authors: Carolyn Y. Johnson Source Type: news
Bluebird's lovo-cel application finally lands at the FDA's desk
After being hit with a partial clinical hold for its gene therapy back in | After a partial clinical hold caused bluebird to miss its own first-quarter FDA filing goal, the company says its sickle cell disease gene therapy application is in.#fda (Source: Reuters: Health)
Source: Reuters: Health - April 25, 2023 Category: Consumer Health News Source Type: news
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
SOMERVILLE, Mass.--(BUSINESS WIRE)--Apr. 24, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 24, 2023 Category: Drugs & Pharmacology Source Type: news
TKA Complications Increased for Sickle Cell Disease Patients
FRIDAY, April 21, 2023 -- Patients with sickle cell disease (SCD) undergoing total knee arthroplasty (TKA) have longer length of stay, incur greater health care costs, and have an increased risk for complications during the perioperative period,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 21, 2023 Category: Pharmaceuticals Source Type: news
